Dr. Yizhuo Zhang 张翼鷟
Chief Physician
Department of Pediatric Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of leukemia, lymphoma, and pediatric solid tumors. Performs hematopoietic stem cell transplantation for hematologic malignancies.
Dr. Zhang holds a PhD in Hematology from the General Hospital of the People's Liberation Army (2004) and was a visiting scholar at St-Antoine Hospital, Paris. Previously Director of Hematology and Stem Cell Transplantation at Tianjin Medical University Cancer Institute, Dr. Zhang joined Sun Yat-sen University Cancer Center in 2018 as Director of Pediatric Oncology. Research focuses on targeted therapies for acute leukemia and lymphoma.
Professional roles
- Vice Chair and Secretary-General, Hematologic Disease Translational Medicine Committee, China Anti-Cancer Association
- Standing Committee Member, Hematologic Oncology Committee, China Anti-Cancer Association
- Standing Committee Member, CSCO Anti-Lymphoma Alliance
- Corresponding Editorial Board Member, Chinese Journal of Hematology
Name order: in Chinese the family name comes first (Zhang Yizhuo). Papers usually list the name as Yizhuo Zhang or Zhang Y.
Selected publications
80 papers on PubMed matched by name and affiliation; 30 as first or senior author since 2016. Most recent first- or senior-author papers:
- MedComm (2020), 2026 (senior author): Safety, Efficacy, and Pharmacokinetics of Unecritinib (TQ-B3101) in Pediatric Patients With Relapsed/Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large-Cell Lymphoma: A Phase I Study. PubMed 42996901
- Exp Hematol Oncol, 2026 (senior author): Chimeric antigen receptor (CAR)-T cell therapy for solid tumors in pediatric patients: current breakthroughs, dilemmas, and strategies. PubMed 42701195
- Front Immunol, 2025 (senior author): Safety and efficacy of sintilimab versus pembrolizumab in the treatment of advanced or recurrent pediatric malignancies: a real-world study in China. PubMed 40547017
- EClinicalMedicine, 2025 (senior author): Safety and feasibility of anlotinib in children with high risk, recurrent or refractory sarcomas: an open-label, single-centre, single-arm, phase Ia/Ib trial. PubMed 40496885
- Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2024 (senior author): [Influence of Methylenetetrahydrofolate Reductase C677T Polymorphism on High-Dose Methotrexate Toxicity in Pediatric Mature B-cell lymphoma Patients]. PubMed 39743258
- Front Pharmacol, 2024 (senior author): Efficacy, safety, and cost-effectiveness of pegylated PEG-rhg-CSF in pediatric patients receiving high-intensity chemotherapy: results from a phase II study. PubMed 39086394
- EClinicalMedicine, 2024 (senior author): Pegylated liposomal doxorubicin combined with cyclophosphamide and vincristine in pediatric patients with relapsed/refractory solid tumor: a single-arm, open-label, phase I study. PubMed 39007065
- Cancer Biol Med, 2024 (senior author): Current therapeutic landscape and resistance mechanisms to larotrectinib. PubMed 38318928
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion